Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stake Lifted by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 631.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 3,087,208 shares of the biopharmaceutical company’s stock after buying an additional 2,664,915 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 4.68% of Celldex Therapeutics worth $129,571,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its position in shares of Celldex Therapeutics by 4.6% during the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock worth $852,000 after buying an additional 954 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Celldex Therapeutics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 962 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Celldex Therapeutics by 10.0% in the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the period. Finally, Strs Ohio grew its position in Celldex Therapeutics by 92.9% in the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 1,300 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. Stifel Nicolaus started coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, July 16th. Finally, Wolfe Research initiated coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Stock Down 3.8 %

Celldex Therapeutics stock traded down $1.69 during mid-day trading on Monday, hitting $42.87. The company’s stock had a trading volume of 104,369 shares, compared to its average volume of 779,136. Celldex Therapeutics, Inc. has a twelve month low of $22.11 and a twelve month high of $53.18. The stock’s fifty day moving average price is $36.66 and its two-hundred day moving average price is $39.18. The stock has a market capitalization of $2.83 billion, a P/E ratio of -15.51 and a beta of 1.58.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. Equities analysts expect that Celldex Therapeutics, Inc. will post -2.39 earnings per share for the current year.

Insider Activity

In related news, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the transaction, the chief financial officer now owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Celldex Therapeutics news, VP Richard M. Wright sold 46,844 shares of Celldex Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $33.72, for a total transaction of $1,579,579.68. Following the transaction, the vice president now owns 20,833 shares of the company’s stock, valued at approximately $702,488.76. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Samuel Bates Martin sold 35,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the transaction, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The disclosure for this sale can be found here. Insiders have sold 266,332 shares of company stock worth $9,155,821 over the last 90 days. 3.80% of the stock is owned by company insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.